Diagnostics

Emocha adds another wrinkle to mHealth business in deal with diagnostic lab test developer

The partnership will support the development of a mobile application to give users easy access to a diagnostic device to initiate diagnostic tests and view results on their mobile devices.

bigstock-Medical-Abstract-in-Science-an-15767099

A diagnostic test developer, miDIAGNOSTICS, has inked a deal with a Baltimore-based healthcare startup emocha to provide a way to conduct diagnostic tests through silicon chips and transmit those lab test results through the cloud, according to a press release.

The goal of miDIAGNOSTICS, a company formed by Johns Hopkins University and Belgian nano-electronics research center imec, is to create a mini-lab of sorts. Its partnership with emocha is designed to make that process faster and more convenient. At the same time, it raises the issue of how much sensitive personal health information one wants to tote around on their smartphone, no matter how secure the info.

miDIAGNOSTICS’ approach relies on a few drops of blood. The company’s technology could be used to do a complete blood count test — either to diagnose disease or to monitor a medical condition, a Baltimore Sun article noted.

Here’s a short description of the miDIAGNOSTICS’ approach from CEO Hilja Ibert:

“[E]mocha adds mobile data management to our diagnostic devices. They will complement our products with a mobile application, cloud infrastructure, and dashboards. The mobile application will give users easy access to a diagnostic device to initiate tests and view results on their mobile devices. The cloud infrastructure is the central hub transforming future miDIAGNOSTICS’ products into impactful mobile health solutions that links patient results to providers and health system electronic record. Finally, the dashboard will offer a customizable view of test results, allowing consolidation of tests and data analysis.”

Emocha has been developing a mobile platform to support directly observed therapy needs, referred to as miDOT, for conditions such as drug-resistant tuberculosis and Hepatitis C. The miDOT application allows users to record themselves on a smartphone or a computer taking medication and transmit that recording to a physician.

Emocha Co-founder and CEO Sebastian Seiguer said in the release that he hopes to add miDIAGNOSTICS to its mobile health interventions for use cases such as Hepatitis C medication adherence.

Seiguer said: “Care has shifted rapidly to the outpatient setting, and our integrated solutions will enable providers to strongly support patients wherever they may be.”

Photo: Bigstock